BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Pertuzumab: trial readouts and FDA decisions

1 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 2 readout(s) in the last 180 days and 0 FDA event(s) in the last 12 months. Sponsors: Shanghai JMT-Bio Inc., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., RemeGen Co., Ltd.. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12-16 est.P3Shanghai JMT-Bio Inc.NCT06747338 A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast CancerEarly or Locally Advanced HER2-positive Breast Canceractive not recruiting520

Readouts, last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-07-15 est.P2CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT07116824 HB1801 Combined Treatment of HER2-positive Breast CancerHER2-positive Breast Cancernot yet recruiting80
2026-06 est.P2RemeGen Co., Ltd.NCT06178159 DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast CancerBreast Cancerrecruiting40

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.